---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-26-000035"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:36:42.758987+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia to acquire Kezar for $6.955/share plus CVR; tender offer by April 13

## Summary
- Aurinia (AUPH) to acquire Kezar (KZR) for $6.955 per share in cash plus one non-transferable CVR.
- CVR entitles holders to potential payments from zetomipzomib milestones, Everest/Enodia proceeds, and Kezar's net cash over $50M.
- Kezar's lead asset zetomipzomib is a first-in-class immunoproteasome inhibitor for autoimmune hepatitis and lupus.
- Tang Capital Partners (9% holder) signed support agreement to tender shares; deal expected to close Q2 2026.
- Kezar's board unanimously approved; TD Cowen and Cooley advised Kezar.

## SEC filing metadata
- accession: 0001600620-26-000035
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000035/0001600620-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000035/auph-20260330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-26-000035
- JSON: https://secwatch.observer/filing/0001600620-26-000035.json
- Plain text: https://secwatch.observer/filing/0001600620-26-000035.txt

## Source-grounded claims
- claim_id: 54a3a4811a8521a64c02476c535aefee96262fca
  claim: Aurinia Pharmaceuticals Inc. entered into Agreement and Plan of Merger with Kezar Life Sciences, Inc. (effective 2026-03-30).
  evidence_excerpt: On March 30, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation (“Parent”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Kezar Life Sciences, Inc., a Delaware corporation (the “Company” or “Kezar”), Parent, Aurinia Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub” and together with Parent, the “Buyer Entities”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000035/0001600620-26-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.